Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Project Grant

McGill University

$100,000.00

Individualized prognosis and prediction of cognitive decline in cognitively normal individuals at risk of AD

FY 2018-19

Summary
Alzheimer's disease (AD) pathology is present in the brain 10-15 years before symptoms occur. As in most diseases, early treatment, before too much brain damage has been done, is likely to be more effective. However, accurately identifying people at risk of dementia due to AD early, before symptoms appear, is extremely difficult. We propose to study people with subjective cognitive decline (SCD) - they have issues with their memory or cognition, but not enough to be captured by standard cognitive tests. Such people have significantly increased risk of later dementia and are thus a logical group to study when looking at preclinical AD. Through multiple collaborations, we have built a database of MRI, cognitive and clinical data, with extensive follow up information from 4000+ subjects. We will use this data to develop and validate our DaMoCLES (Decline prediction using MRI, Cognition and LifEStyle) metric. DaMoCLES will combine (1) clinically available cardiovascular risk lifestyle factors known to be associated with cognitive decline, (2) tests of cognition that can be completed quickly in the clinic, and (3) results from sophisticated magnetic resonance imaging (MRI) analysis to detect patterns of brain atrophy typical of AD. DaMoCLES will be a clinically useful tool to determine which individual asymptomatic subjects will develop cognitive decline. (DaMoCLES will also be applicable in MCI to determine progression to AD, thus aiding in individualized prognosis in both preclinical and prodromal AD.) The DaMoCLES score will help clinicians to enable optimal treatment for patients. In addition, the DaMoCLES score will enable enrichment of populations studied in clinical trials, so that only people that are likely to get worse are included in the trials, and any benefit of the drug easier to see. This makes clinical trials more powerful, allowing drugs to be properly tested with fewer subjects over shorter durations, bringing new treatments to patients sooner.
Program
Project Grant
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
387288
Name
Collins Donald L
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Biological and Clinical Aspects of Aging
Projecttitle
Individualized prognosis and prediction of cognitive decline in cognitively normal individuals at risk of AD
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Aging; Alzheimer'S Disease; Biomarker; Cognitive Decline; Cognitive Testing; Dementia; Image Processing; Magnetic Resonance Imaging; Prognosis
Abstract
Alzheimer's disease (AD) pathology is present in the brain 10-15 years before symptoms occur. As in most diseases, early treatment, before too much brain damage has been done, is likely to be more effective. However, accurately identifying people at risk of dementia due to AD early, before symptoms appear, is extremely difficult. We propose to study people with subjective cognitive decline (SCD) - they have issues with their memory or cognition, but not enough to be captured by standard cognitive tests. Such people have significantly increased risk of later dementia and are thus a logical group to study when looking at preclinical AD. Through multiple collaborations, we have built a database of MRI, cognitive and clinical data, with extensive follow up information from 4000+ subjects. We will use this data to develop and validate our DaMoCLES (Decline prediction using MRI, Cognition and LifEStyle) metric. DaMoCLES will combine (1) clinically available cardiovascular risk lifestyle factors known to be associated with cognitive decline, (2) tests of cognition that can be completed quickly in the clinic, and (3) results from sophisticated magnetic resonance imaging (MRI) analysis to detect patterns of brain atrophy typical of AD. DaMoCLES will be a clinically useful tool to determine which individual asymptomatic subjects will develop cognitive decline. (DaMoCLES will also be applicable in MCI to determine progression to AD, thus aiding in individualized prognosis in both preclinical and prodromal AD.) The DaMoCLES score will help clinicians to enable optimal treatment for patients. In addition, the DaMoCLES score will enable enrichment of populations studied in clinical trials, so that only people that are likely to get worse are included in the trials, and any benefit of the drug easier to see. This makes clinical trials more powerful, allowing drugs to be properly tested with fewer subjects over shorter durations, bringing new treatments to patients sooner.
Competitiondate
201804
Approvedterm2
1 yr 0 mth
Pinamesdelim
Collins, Donald L
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~